ホーム › 卵巣がん › ペンシルベニア › Philadelphia
Philadelphia、PAにおける卵巣がんの臨床試験
Philadelphiaとその周辺地域（約30マイル以内）の拠点で、卵巣がんに関する44件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
被験者募集中第2/3相
- Thomas Jefferson University Hospital, Philadelphia
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
被験者募集中第2相
- Pennsylvania Hospital, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
- Fox Chase Cancer Center, Philadelphia
- 他4件
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- Sidney Kimmell Cancer Center - Jefferson Health, Philadelphia
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
被験者募集中
- University of Pennsylvania, Philadelphia
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
被験者募集中第2相
- University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 275612, Philadelphia
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
被験者募集中第2相
- Site 0232 - University of Pennsylvania, Philadelphia
- Site 0178 - Thomas Jefferson University, Philadelphia
Study of AVZO-021 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- Avenzo Therapeutics Recruiting Site, Philadelphia
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
被験者募集中第1/2相
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
被験者募集中第3相
- University of Pennsylvania Hospital, Philadelphia
- Jefferson Health Honickman Center, Philadelphia
- Asplundh Cancer Pavilion, Willow Grove · 13マイル先
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
被験者募集中第1相
- University of Pennsylvania, Philadelphia
- Fox Chase Cancer Center, Philadelphia
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
被験者募集中第2相
- Penn Medicine University of Pennsylvania Health System /ID# 277963, Philadelphia
Prehabilitation in High-risk Oncologic Surgery
被験者募集中
- Fox Chase Cancer Center - Philadelphia, Philadelphia
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
被験者募集中第1/2相
- University of Pennsylvania, Philadelphia
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
被験者募集中第3相
- Hospital of the University of Pennsylvania ( Site 0071), Philadelphia
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
被験者募集中第3相
- Lankenau Medical Center, Wynnewood · 7マイル先
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
被験者募集中観察研究
- University of Pennsylvania, Philadelphia
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
被験者募集中第1相
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
被験者募集中第1/2相
- Children's Hospital of Philadelphia, Philadelphia
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
被験者募集中第1相
- Sidney Kimmel Comprehensive Center at Jefferson, Philadelphia
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
被験者募集中第1相
- SCRI - Sydney Kimmel Cancer Center - Jefferson Health, Philadelphia
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
被験者募集中第1相
- Normunity Investigational Site, Philadelphia
- Normunity Investigational Site, Philadelphia
The Appendix Cancer PMP Research Foundation Natural History Study/Patient Registry
被験者募集中観察研究
- ACPMP, Springfield · 8マイル先
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
被験者募集中第3相
- Site 0109, Philadelphia
- Site 0113, Philadelphia
- Site 0114, Willow Grove · 13マイル先
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
被験者募集中
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
- Fox Chase Cancer Center, Philadelphia
- Lankenau Medical Center, Wynnewood · 7マイル先
- 他5件
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
被験者募集中第3相
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
- Pennsylvania Hospital, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
- 他5件
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- University of Pennsylvania / Abramson Cancer Center, Philadelphia
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization, Philadelphia
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
被験者募集中第2/3相
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
被験者募集中第2相
- Thomas Jefferson University, Philadelphia
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Investigative Site #109, Philadelphia
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
被験者募集中第2相
- University of Pennsylvania Health System, Perelman Center for Advanced Medicine, Philadelphia
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
被験者募集中第1相
- University of Pennsylvania, Philadelphia
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
被験者募集中第1相
- Penn Medicine - Perelman Center for Advanced Medicine, Philadelphia
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
被験者募集中第1/2相
- University of Pennsylvania, Perelamn Center for Advanced Medicine, Philadelphia
- Thomas Jefferson University, Honickman Center, Philadelphia
- Fox Chase Cancer Center, Philadelphia
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
被験者募集中第3相
- Lankenau Medical Center/Mainline Medical Center, Wynnewood · 7マイル先
- Jefferson Abington Hospital, Abington · 12マイル先
- Asplundh Cancer Pavilion, Willow Grove · 13マイル先
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
被験者募集中
- Hospital of the University of Pennsylvania, Philadelphia
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
被験者募集中第1/2相
- Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center, Philadelphia
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
被験者募集中第1相
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
- Fox Chase Cancer Center, Philadelphia
Healthy Volunteers Study
被験者募集中観察研究健康なボランティア歓迎
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
被験者募集中第2相
- University of Pennsylvania, Philadelphia
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Philadelphia
Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
被験者募集中第2相
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
被験者募集中観察研究
- Gynecologic Oncology Group, Philadelphia
他の都市における卵巣がんの試験
- Houston, TX89件の研究
- New York City, NY69件の研究
- Boston, MA61件の研究
- Los Angeles, CA50件の研究
- Nashville, TN49件の研究
- Arlington, VA46件の研究
- Columbus, OH39件の研究
- St. Louis, MO38件の研究
- Chicago, IL36件の研究
- San Antonio, TX31件の研究
- Cleveland, OH30件の研究
- Pittsburgh, PA30件の研究
Philadelphiaにおける他の研究
- がん（全種類）59件の研究
- 乳がん56件の研究
- 非小細胞肺癌51件の研究
- 転移性癌46件の研究
- 前立腺がん44件の研究
- 大腸癌44件の研究
- 肺がん36件の研究
- 急性骨髄性白血病34件の研究
- 心不全31件の研究
- 子宮内膜がん28件の研究
- うつ病26件の研究
- 膵臓がん26件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。